Shenzhen New Industries Biomedical (300832) - Net Assets
Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has net assets worth CN¥8.74 Billion CNY (≈ $1.28 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.58 Billion ≈ $1.40 Billion USD) and total liabilities (CN¥831.98 Million ≈ $121.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300832 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.74 Billion |
| % of Total Assets | 91.31% |
| Annual Growth Rate | 34.34% |
| 5-Year Change | 78.52% |
| 10-Year Change | 738.27% |
| Growth Volatility | 18.31 |
Shenzhen New Industries Biomedical - Net Assets Trend (2012–2024)
This chart illustrates how Shenzhen New Industries Biomedical's net assets have evolved over time, based on quarterly financial data. Also explore Shenzhen New Industries Biomedical asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Shenzhen New Industries Biomedical (2012–2024)
The table below shows the annual net assets of Shenzhen New Industries Biomedical from 2012 to 2024. For live valuation and market cap data, see Shenzhen New Industries Biomedical stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.58 Billion ≈ $1.26 Billion |
+13.68% |
| 2023-12-31 | CN¥7.54 Billion ≈ $1.10 Billion |
+17.89% |
| 2022-12-31 | CN¥6.40 Billion ≈ $936.45 Million |
+14.03% |
| 2021-12-31 | CN¥5.61 Billion ≈ $821.21 Million |
+16.81% |
| 2020-12-31 | CN¥4.80 Billion ≈ $703.01 Million |
+53.06% |
| 2019-12-31 | CN¥3.14 Billion ≈ $459.30 Million |
+32.65% |
| 2018-12-31 | CN¥2.37 Billion ≈ $346.26 Million |
+33.52% |
| 2017-12-31 | CN¥1.77 Billion ≈ $259.33 Million |
+24.87% |
| 2016-12-31 | CN¥1.42 Billion ≈ $207.68 Million |
+38.72% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.72 Million |
+67.59% |
| 2014-12-31 | CN¥610.52 Million ≈ $89.34 Million |
+61.15% |
| 2013-12-31 | CN¥378.84 Million ≈ $55.44 Million |
+52.65% |
| 2012-12-31 | CN¥248.18 Million ≈ $36.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen New Industries Biomedical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11767.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.02 Billion | 70.24% |
| Common Stock | CN¥785.72 Million | 9.16% |
| Other Components | CN¥1.77 Billion | 20.60% |
| Total Equity | CN¥8.58 Billion | 100.00% |
Shenzhen New Industries Biomedical Competitors by Market Cap
The table below lists competitors of Shenzhen New Industries Biomedical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PTT Global Chemical Public Company Limited
BK:PTTGC
|
$5.55 Billion |
|
Olympic Circuit Technology Co Ltd
SHG:603920
|
$5.55 Billion |
|
Reinet Investments SCA
JSE:RNI
|
$5.56 Billion |
|
Gerdau S.A
MX:GGBN
|
$5.56 Billion |
|
Compagnie de l'Odet
PA:ODET
|
$5.55 Billion |
|
Porsche Automobil Holding SE
XETRA:PAH3
|
$5.55 Billion |
|
Jiangsu Lettall Electronic Co Ltd
SHG:603629
|
$5.54 Billion |
|
TKMS AG & Co KGaA
XETRA:TKMS
|
$5.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen New Industries Biomedical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,544,400,237 to 8,576,607,474, a change of 1,032,207,237 (13.7%).
- Net income of 1,828,456,619 contributed positively to equity growth.
- Dividend payments of 785,964,139 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.83 Billion | +21.32% |
| Dividends Paid | CN¥785.96 Million | -9.16% |
| Other Changes | CN¥-10.29 Million | -0.12% |
| Total Change | CN¥- | 13.68% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen New Industries Biomedical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 133.12x to 4.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.36 | CN¥48.25 | x |
| 2013-12-31 | CN¥0.55 | CN¥48.25 | x |
| 2014-12-31 | CN¥0.89 | CN¥48.25 | x |
| 2015-12-31 | CN¥1.48 | CN¥48.25 | x |
| 2016-12-31 | CN¥2.02 | CN¥48.25 | x |
| 2017-12-31 | CN¥2.52 | CN¥48.25 | x |
| 2018-12-31 | CN¥3.36 | CN¥48.25 | x |
| 2019-12-31 | CN¥4.01 | CN¥48.25 | x |
| 2020-12-31 | CN¥6.14 | CN¥48.25 | x |
| 2021-12-31 | CN¥7.14 | CN¥48.25 | x |
| 2022-12-31 | CN¥8.14 | CN¥48.25 | x |
| 2023-12-31 | CN¥9.60 | CN¥48.25 | x |
| 2024-12-31 | CN¥10.92 | CN¥48.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen New Industries Biomedical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.32%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 40.32%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.12x
- Recent ROE (21.32%) is below the historical average (26.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 30.27% | 29.11% | 0.82x | 1.26x | CN¥50.31 Million |
| 2013 | 37.29% | 37.36% | 0.70x | 1.43x | CN¥103.38 Million |
| 2014 | 41.42% | 46.38% | 0.73x | 1.22x | CN¥191.82 Million |
| 2015 | 24.35% | 34.05% | 0.64x | 1.12x | CN¥146.81 Million |
| 2016 | 31.83% | 48.96% | 0.57x | 1.13x | CN¥309.77 Million |
| 2017 | 30.37% | 47.19% | 0.56x | 1.14x | CN¥360.98 Million |
| 2018 | 29.33% | 50.16% | 0.52x | 1.12x | CN¥457.37 Million |
| 2019 | 24.61% | 45.95% | 0.49x | 1.10x | CN¥458.73 Million |
| 2020 | 19.55% | 42.79% | 0.41x | 1.10x | CN¥458.73 Million |
| 2021 | 17.35% | 38.25% | 0.41x | 1.09x | CN¥412.50 Million |
| 2022 | 20.75% | 43.58% | 0.43x | 1.10x | CN¥687.97 Million |
| 2023 | 21.92% | 42.08% | 0.48x | 1.09x | CN¥899.21 Million |
| 2024 | 21.32% | 40.32% | 0.47x | 1.12x | CN¥970.80 Million |
Industry Comparison
This section compares Shenzhen New Industries Biomedical's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,988,006,983
- Average return on equity (ROE) among peers: 15.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen New Industries Biomedical (300832) | CN¥8.74 Billion | 30.27% | 0.10x | $5.55 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.09 Billion | 22.08% | 0.18x | $449.34 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $4.30 Billion |
| Double Medical Technology Inc (002901) | $1.46 Billion | 25.48% | 0.14x | $2.63 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $615.62 Million | 6.75% | 0.04x | $577.41 Million |
| Lepu Medical Tech Beijing (300003) | $3.29 Billion | 12.85% | 0.16x | $3.87 Billion |
| INKON Life Technology Co Ltd (300143) | $810.78 Million | 0.80% | 0.23x | $1.23 Billion |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $1.26 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.03 Billion | 33.51% | 0.56x | $685.28 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.80 Billion | 0.85% | 0.07x | $534.16 Million |
| Sinocare Inc (300298) | $3.47 Billion | 8.19% | 0.71x | $1.36 Billion |
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more